|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Pure Communications Release: Ember Therapeutics Secures Exclusive License to Key Brown Fat Technology and Intellectual Property from the Joslin Diabetes Center
3/28/2012 6:52:41 AM
BOSTON--(BUSINESS WIRE)--Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the completion of an agreement with the Joslin Diabetes Center to exclusively license intellectual property covering bone morphogenetic protein 7 (BMP7), which has been shown to play a role in the regulation of brown fat development. Research on this BMP7 technology was led by Yu-Hua Tseng, Ph.D., Aaron Cypess, M.D., Ph.D., and C. Ronald Kahn, M.D., of Harvard Medical School and the Joslin Diabetes Center, and is detailed in a key 2008 Nature paper outlining the important role of BMP7 in promoting brown fat precursor cells. Dr. Kahn is also a scientific co-founder of Ember.
|
|
|
|
|
|
|
|
|
|
|